Healthcare / Medical DevicesTokyo
$815.00
-27.00 (-3.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $302.5M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$21.5B
P/E
81.3x
↑EV/EBITDA
15.4x
↑ROE
-1.9%
↓Gross Margin
62.3%
↑Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.4%
FCF CAGR
—
FCF margin
-2.5%
FCF / Net income
1.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.11B · net income $-461.8M · FCF $-619.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.11B | $25.11B | $23.18B | $21.31B | $19.19B |
| Net Income | $-461.8M | $-461.8M | $1.27B | $1.42B | $2.14B |
| EBITDA | $1.40B | $1.40B | $3.26B | $3.34B | $4.20B |
| EPS | -17.50 | -17.50 | 48.31 | 54.03 | 80.95 |
| Gross Margin | 62.3% | 62.3% | 63.7% | 65.7% | 67.7% |
| Operating Margin | 6.2% | 6.2% | 7.5% | 9.5% | 13.9% |
| Net Margin | -1.8% | -1.8% | 5.5% | 6.7% | 11.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.06 | 0.08 | 0.09 |
| Current Ratio | 3.23 | 3.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-619.9M | $-619.9M | $302.5M | $870.7M | $1.53B |
| Returns | |||||
| ROE | -1.9% | -1.9% | 5.0% | 6.1% | 10.0% |
| Valuation | |||||
| P/E | 81.34 | 81.34 | 14.57 | 18.51 | 20.79 |
| EV/EBITDA | 15.39 | 15.39 | 5.42 | 7.62 | 10.39 |
| P/B | 0.87 | 0.87 | 0.73 | 1.14 | 2.08 |
| Growth & Yield | |||||
| Revenue Growth | 8.4% | 8.4% | 8.8% | 11.0% | — |
| EPS Growth | -136.2% | -136.2% | -10.6% | -33.3% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+50.7%
Start / end P/E
n/dx → n/dx
EPS bridge
48.31 → -17.50
Residual
+48.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.